Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.

Mol Cancer 2014 Jan 24;13:13. Epub 2014 Jan 24.

Singapore OncoGenome Laboratory, Institute of Medical Biology, Agency of Science Technology and Research, Singapore, Singapore.

The advent of effective targeted therapeutics has led to increasing emphasis on precise biomarkers for accurate patient stratification. Here, we describe the role of ACK1, a non-receptor tyrosine kinase in abrogating migration and invasion in KRAS mutant lung adenocarcinoma. Bosutinib, which inhibits ACK1 at 2.7 nM IC50, was found to inhibit cell migration and invasion but not viability in a panel of non-small cell lung cancer (NSCLC) cell lines. Knockdown of ACK1 abrogated bosutinib-induced inhibition of cell migration and invasion specifically in KRAS mutant cells. This finding was further confirmed in an in vivo zebrafish metastatic model. Tissue microarray data on 210 Singaporean lung adenocarcinomas indicate that cytoplasmic ACK1 was significantly over-expressed relative to paired adjacent non-tumor tissue. Interestingly, ACK1 expression in "normal" tissue adjacent to tumour, but not tumour, was independently associated with poor overall and relapse-free survival. In conclusion, inhibition of ACK1 with bosutinib attenuates migration and invasion in the context of KRAS mutant NSCLC and may fulfil a therapeutic niche through combinatorial treatment approaches.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-13-13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930897PMC
January 2014

Publication Analysis

Top Keywords

migration invasion
20
kras mutant
16
non-small cell
8
lung cancer
8
cell lung
8
cell migration
8
invasion kras
8
bosutinib inhibits
8
ack1
7
cell
5
migration
5
invasion
5
210 singaporean
4
metastatic model
4
model tissue
4
tissue microarray
4
data 210
4
microarray data
4
adenocarcinomas indicate
4
ack1 over-expressed
4

Similar Publications